Department of Urology and Transplant Surgery, Toda Chuo General Hospital, Saitama, Japan.
Department of Urology and Transplant Surgery, Toda Chuo General Hospital, Saitama, Japan.
Transplant Proc. 2022 Jul-Aug;54(6):1551-1553. doi: 10.1016/j.transproceed.2021.10.004. Epub 2021 Oct 15.
Patients undergoing organ transplantation are immunosuppressed and already at risk of various diseases. We report about a patient who underwent ABO-incompatible kidney transplantation after coronavirus disease 2019 (COVID-19) without a recurrence of infection.
A 68-year-old woman presented with end-stage renal failure owing to primary autosomal dominant polycystic kidney disease; accordingly, hemodialysis was initiated in September 2020. Her medical history included bilateral osteoarthritis, lumbar spinal stenosis, hypertension, and hyperuricemia. In mid-January 2021, she contracted severe acute respiratory syndrome coronavirus 2 infection from her husband. Both of them were hospitalized and received conservative treatment. Because their symptoms were mild, they were discharged after 10 days. The patient subsequently underwent ABO-incompatible kidney transplantation from her husband who recovered from COVID-19 in March 2021. Before kidney transplantation, her COVID-19 polymerase chain reaction test was negative, confirming the absence of pre-existing COVID-19 immediately before the procedure. Computed tomography revealed no pneumonia. Initial immunosuppression was induced by administering tacrolimus, mycophenolate mofetil, methylprednisolone, basiliximab, rituximab, and 30 g of intravenous immunoglobulin. Double-filtration plasmapheresis and plasma exchange were performed once before ABO-incompatible kidney transplantation. The renal allograft functioned immediately, and the postoperative course was normal without rejection. COVID-19 did not recur. In addition, her serum creatinine levels and renal function had otherwise remained stable.
Living kidney transplantation was safely performed in a patient with COVID-19 without postoperative complications or rejection. During the COVID-19 pandemic, the possibility of severe acute respiratory syndrome coronavirus 2 infection during transplantation surgery must be considered.
接受器官移植的患者会接受免疫抑制治疗,且已经面临多种疾病的风险。我们报告了一例在感染新型冠状病毒病 2019(COVID-19)后未复发感染的情况下接受 ABO 血型不合肾移植的患者。
一名 68 岁女性因常染色体显性多囊肾病导致终末期肾病,因此于 2020 年 9 月开始血液透析。其既往病史包括双侧骨关节炎、腰椎椎管狭窄症、高血压和高尿酸血症。2021 年 1 月中旬,她从丈夫那里感染了严重急性呼吸综合征冠状病毒 2。他们都住院并接受了保守治疗。由于症状轻微,他们在 10 天后出院。此后,患者于 2021 年 3 月从已从 COVID-19 中康复的丈夫那里接受了 ABO 血型不合的肾移植。在肾移植前,她的 COVID-19 聚合酶链反应检测结果为阴性,证实了在手术前没有 COVID-19 既往感染。计算机断层扫描显示没有肺炎。初始免疫抑制通过给予他克莫司、霉酚酸酯、甲基强的松龙、巴利昔单抗、利妥昔单抗和 30g 静脉注射免疫球蛋白来诱导。在 ABO 血型不合肾移植前进行了一次双重滤过血浆置换和血浆交换。移植后肾移植功能立即恢复,术后过程正常,无排斥反应。COVID-19 未复发。此外,她的血清肌酐水平和肾功能一直保持稳定。
在没有术后并发症或排斥反应的情况下,对 COVID-19 患者成功进行了活体肾移植。在 COVID-19 大流行期间,必须考虑移植手术过程中感染严重急性呼吸综合征冠状病毒 2 的可能性。